Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26137553 | 0.80 | RPS6KA3 (0.36) | RPS6KA3EIF4A3CA1CA2GABRA1 | |
| SCHEMBL25879873 | 0.79 | LMNA (0.39) | CA1CA2GABRA1GABRB2LMNA | |
| SCHEMBL25928132 | 0.76 | GABRA1 (0.33) | GABRA1GABRB1 | |
| SCHEMBL26138259 | 0.76 | P2RX3 (0.36) | LMNAHTR2B | |
| SCHEMBL31128303 | 0.71 | NQO2 (0.39) | LMNAHPGDVRK1 | |
| SCHEMBL23333005 | 0.68 | GCGR (0.31) | — | |
| SCHEMBL24868481 | 0.68 | ESR1 (0.34) | GABRA1GABRB2LMNATSHRVRK1 | |
| SCHEMBL24249176 | 0.68 | VRK1 (0.30) | VRK1 | |
| SCHEMBL31128300 | 0.68 | GABRA1 (0.42) | CA1CA2GABRA1GABRB2LMNA | |
| SCHEMBL25928145 | 0.68 | GABRA1 (0.33) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | RPS6KA3 590/4885EIF4A3 284/4885CA1 4843/4885 |
| US-20230027684-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | RPS6KA3 590/4885EIF4A3 284/4885CA1 4843/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | RPS6KA3 590/4885EIF4A3 284/4885CA1 4843/4885 |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | RPS6KA3 599/4885EIF4A3 270/4885CA1 4780/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | RPS6KA3 590/4885EIF4A3 284/4885CA1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.